Huddart RA, Hall E, Lewis R, et al. - In the present study, the researchers analyzed the impact of treatment on the health-related quality of life (HRQoL) of BC2001, the largest randomised trial of bladder-sparing treatment for muscle-invasive bladder cancer, candidates. Study participants included 458 UK individuals with T2-T4a N0 M0 transitional cell carcinoma of the bladder. Information was available for 331 and 204 candidates at baseline and for 192 and 114 at 12 months for the chemotherapy and radiotherapy comparisons, respectively. A significant proportion of patients record reductions in HRQoL immediately following (chemo)radiotherapy, which improves to baseline after 6 months. During long-term follow-up, two-thirds of patients report stable or improved HRQoL. There is no evidence of impairment caused by the addition of chemotherapy in HRQoL.